MyMyelomaTeam

Several significant advances in treating relapsed multiple myeloma have emerged. One major development is the approval of BCMA-targeted antibodies for patients who have undergone at least four previous lines of therapy. These new antibodies specifically bind to the BCMA protein on myeloma cells, offering a new treatment Show Full Answer

Several significant advances in treating relapsed multiple myeloma have emerged. One major development is the approval of BCMA-targeted antibodies for patients who have undergone at least four previous lines of therapy. These new antibodies specifically bind to the BCMA protein on myeloma cells, offering a new treatment approach for patients who have become resistant to standard therapies. Additional treatment options include new combinations of existing therapies. The FDA has approved several powerful combinations, including bortezomib with daratumumab and dexamethasone, as well as lenalidomide with daratumumab and dexamethasone. These combination approaches provide more options for patients experiencing early relapses.

For patients who have had multiple relapses, genetic testing is now being used more frequently to identify specific mutations in myeloma cells. This allows for more targeted treatment approaches, potentially improving treatment effectiveness even in cases where the disease has become resistant to multiple previous therapies.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Myeloma Relapse Rates and 9 Treatment Options for Relapses